OPNT

Opiant Pharmaceuticals, Inc. (OPNT) | Rumor.io

Opiant Pharmaceuticals

OPNT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about OPNT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Nov 19

The OPN Tokenization Platform is going live tomorrow, and users are encouraged to perform swap transactions and add liquidity to various pairs.
Users are sharing their daily routines on the OPN testnet, which typically involve claiming faucet tokens, swapping between $OPN, $OPNT, $tUSDT, and $tBNB, and adding liquidity to pairs such as $OPN/$OPNT and $OPN/$tUSDT.
Maximizing efficiency on the OPN Chain involves testing the full ecosystem, including faucet claims, high-volume swaps, and adding and removing liquidity, with the goal of maintaining a streak on the testnet.

Generated by AI

Sentiment

Of the messages about OPNT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Nov 10

Converting from $OPN to $OPNT can maximize value growth over time and multiply one's position against new entrants.
The seamless flow of $OPN into $OPNT is a game changer for Web3, capturing the magic of the space perfectly.
$OPNT has massive potential, offering a privacy-first, utility-rich combo of scalable DeFi, sovereign IDs, and AI integration, making it a promising investment opportunity.

Bearish· Apr 29

The company's recent announcement may be seen as overhyped, with some investors questioning the validity of a reported licensing deal.
The stock's recent price action may be due to an overreaction to the announcement, with some investors expecting a return to a lower price point of around $20.
The company's short interest may increase as some investors are shorting the stock ahead of a potential decline, with some users expressing concerns about the company's management and the legitimacy of the announcement.

Generated by AI

Topics

Of the messages about OPNT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	56.18%
Controversies	—	—	—	44.94%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	-1.12%

Earnings· Mar 21

OPNT's earnings are considered old and potentially useless, with new earnings expected soon.
The stock's performance may be influenced by expectations of a buy-out announcement.
The current earnings are likely overshadowed by anticipation of future earnings releases.

Announcements· Nov 14

Opiant Pharmaceuticals, Inc. (OPNT) has entered into a definitive merger agreement to be acquired by Indivior Inc. for $20.00 per share, with contingent value rights (CVRs) worth up to $8.00 per share.
The acquisition is valued at $145 million, with Indivior to pay $20.00 per share at closing and up to $8.00 per share in CVRs if certain revenue thresholds are achieved.
Opiant Pharmaceuticals has announced its third quarter 2022 financial results, with a GAAP EPS of -$1.93 and revenue of $174,000.

Technical Analysis· Jul 7

$OPNT is forming a cup and handle pattern, indicating a potential trend reversal.
The stock has broken support levels and is trending up, with a possible major breakout if it surpasses $18.63.
Historical data suggests that when $OPNT experiences a 53.8% increase in a trading day, it often trades lower by the market close 5 trading days later.

Generated by AI

Community

Of the messages about OPNT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Also Discussed

Investors talking about OPNT also mention

#	Name	Attention
1	Corgi Total U.S. Market 2x Daily ETFUSX	0%0
2	comScore, Inc.SCOR	0%new
3	ITOS - iTeos Therapeutics, Inc.	——
4	Emergent BioSolutions Inc.EBS	0%new
5	Analog Devices Inc.ADI	0%-0.01
6	Allogene Therapeutics IncALLO	0%new
7	Crane NXT, Co.CXT	0%0
8	Sunoco LPSUN	0%new
9	ALTU - Altitude Acquisition Corp.	——
10	EPIX - ESSA Pharma Inc.	——